Centogene Partners with BC Platforms to Launch Rare and Neurodegenerative Disease Biodata Network

Rare Daily Staff

Centogene, a rare disease company focused on providing data-driven answers in rare and neurodegenerative diseases, said it partnered with BC Platforms and launched its Biodata Network, a portfolio of data-driven partnering solutions for biopharma and research institutions.

To offer increased access to Centogene’s data-driven insights, the company has partnered with BC Platforms, a global healthcare data management and analytics firm, to utilize their Global Data Partner Network, BCRQUEST.com. This integrated healthcare data platform creates a connected, secure data source for enabling partners access to datasets for the acceleration and de-risking of target and drug discovery, as well as for optimizing clinical pipelines.

“Ninety-five percent of rare diseases currently do not have an FDA-approved treatment. We see BC Platforms as our ideal partner for the secure and scalable solutions needed for the launch of our Biodata Network, so we can significantly expand the abilities of our partners around the world to drive drug discovery,” said Bettina Goerner, chief data officer at Centogene. “Because of the generous consent given by patients who have contributed their data for research on rare and neurodegenerative diseases, we hope to offer real solutions to patients around the world.”

The addition of these Centogene datasets represents an estimated 20 percent increase in both the breadth and depth of genomic data currently available via BC Platforms. The dataset reflects a diverse geographic and ethnic sample base and includes a large share of pediatric cases in rare and neurodegenerative diseases, with data modalities including clinical, multiomic, and socio-demographic data. This dataset has been made available from the diverse Centogene Biodatabank, which currently contains nearly 700,000 patients represented from over 120 countries, more than 70 percent of whom are of non-European descent.

“By partnering with BC Platforms and launching our Biodata Network Portfolio, we are extending our strategy and expanding our commercialization opportunities to provide partners with yet another model to work with us,” said Kim Stratton, CEO at Centogene.  Ultimately, we want to heal the world of rare and neurodegenerative diseases, and we believe offering greater access to the Centogene Biodatabank will accelerate bringing potentially life-saving therapeutics to patients around the world.”

The Biodata Network portfolio of customizable data-driven partnering solutions includes Biodata Licenses, which enable partners to securely access unique real-world datasets via BC Platform’s cloud-based trusted research environment for self-analysis or optional analysis support; and Insight Reports, tailored data analysis reports generated in close consultation with biopharma partners and Centogene’s in-house geneticists, medical experts, and data scientists to enable institutions to answer ad hoc research questions via curated real-world data.

Photo: Kim Stratton, CEO at Centogene